PYXS
Pyxis Oncology, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.33
−2.35%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$3.42
From 52W high−37.64%
Volume563379.00
Market cap$277.75M
P/E (TTM)—
P/S (TTM)25.2x
Div yield—
Key dataSep 18, 2026
Open
$3.42
From 52W high
−37.64%
Volume
563379.00
Market cap
$277.75M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−3.1x
P/E (TTM)
—
RSI (14)
51.8
MomentumView details →
1D Return
−2.35%
YTD Return
+193.04%
SummaryUpdated Jun 1, 2026
Pyxis Oncology, Inc. (NASDAQ:PYXS) is a preclinical-stage biopharmaceutical company founded in 2018 and headquartered in Cambridge, Massachusetts. The company went public in October 2021 and focuses on developing innovative cancer therapies through two primary technological approaches: immune-oncology treatments and antibody drug conjugates. As a preclinical company, Pyxis is in the early stages of drug development, with its product candidates still undergoing laboratory and early clinical testing before potentially advancing to human trials and eventual commercialization.
Similar companies
Latest newsMore news →
Pyxis Oncology appointed John Flavin as Lead Independent Director, effective September 4, 2026.12d agoPyxis Oncology appointed Thomas Civik as Chief Executive Officer and Chairman of the Board, effective September 4, 2026.12d agoPyxis Oncology reported financial results for the quarter ended June 30, 2026.38d ago